EVM
CLDX icon

Eaton Vance Management’s Celldex Therapeutics CLDX Stock Holding History

Eaton Vance Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-66
Closed -$3K – 1958
2021
Q4 		$3K Hold
66
– – ﹤0.01% 2691
2021
Q3 		$0 Hold
66
– – ﹤0.01% 2116
2021
Q2 		$2K Buy
+66
New +$1.81K ﹤0.01% 2704

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Eaton Vance Management's CLDX Position: Q1 2022 in Review

Eaton Vance Management sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 66 shares — an estimated $3K sold.

Eaton Vance Management first reported a position in CLDX in Q2 2021 and held it in 3 quarters. The position peaked at $3K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

  • Eaton Vance Management reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 66 Celldex Therapeutics shares in Q1 2022, an estimated $3K.
  • Eaton Vance Management first reported a position in Celldex Therapeutics in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Celldex Therapeutics position peaked at $3K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.